Vivianne C G Tjan-Heijnen
Overview
Explore the profile of Vivianne C G Tjan-Heijnen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
171
Citations
3684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Amstel F, Simons J, Tjan-Heijnen V, Smidt M, van Nijnatten T
Insights Imaging
. 2025 Mar;
16(1):51.
PMID: 40050473
No abstract available.
2.
Lenaerts M, van Amstel F, Mottaghy F, Geurts S, Tjan-Heijnen V, Smidt M, et al.
Nucl Med Commun
. 2025 Feb;
PMID: 39998813
The objective is to assess whether the degree of metabolic uptake of the primary tumor and axillary lymph nodes (ALNs) on baseline [18F] fluorodeoxyglucose ([18F]FDG) PET/CT is associated with the...
3.
Ter Welle-Butalid M, Derhaag J, van Bree B, Vriens I, Goddijn M, Balkenende E, et al.
Hum Reprod
. 2024 Oct;
39(12):2693-2701.
PMID: 39479806
Study Question: What are the reproductive outcomes of patients who cryopreserved oocytes or embryos in the context of fertility preservation in the Netherlands? Summary Answer: This study shows that after...
4.
Heesterbeek C, Tjan-Heijnen V, Heimovaara J, Lenaerts L, Lok C, Vriens I, et al.
Lancet Reg Health Eur
. 2024 Sep;
45:101024.
PMID: 39220433
Background: Incidentally, the non-invasive prenatal test (NIPT) shows chromosomal aberrations suspicious of a maternal malignancy, especially after genome-wide testing. The aim of this study is to determine how many cases...
5.
Lammers S, Geurts S, Hermans K, van Hellemond I, Swinkels A, Smorenburg C, et al.
Breast Cancer Res Treat
. 2024 Jun;
208(1):179-192.
PMID: 38940981
Purpose: Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+)...
6.
Heesterbeek C, Lenaerts L, Tjan-Heijnen V, Amant F, van Rij M, Theunis M, et al.
JCO Oncol Pract
. 2024 Apr;
20(8):1027-1034.
PMID: 38608208
In this article, we defined comprehensive recommendations for the clinical follow-up of pregnant women with a malignancy-suspicious NIPT result, on the basis of the vast experience with population-based NIPT screening...
7.
de Wild S, van Roozendaal L, de Wilt J, van Dalen T, van der Hage J, van Duijnhoven F, et al.
Br J Surg
. 2024 Apr;
111(4).
PMID: 38597154
Background: Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in...
8.
Gulikers J, Veerman G, Jebbink M, Kruithof P, Steendam C, Boosman R, et al.
JTO Clin Res Rep
. 2024 Mar;
5(4):100656.
PMID: 38550297
Introduction: Brain metastases (BM) are common in patients with advanced -mutated (m+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic...
9.
Ten Velde D, Duijm L, van der Sangen M, Schipper R, Tjan-Heijnen V, Vreuls W, et al.
Br J Cancer
. 2024 Mar;
130(9):1561-1570.
PMID: 38467826
Background: No studies are available in which changes over time in characteristics and prognosis of patients with interval breast cancers (ICs) and screen-detected breast cancers (SDCs) have been compared. The...
10.
Geurts S, Ibragimova K, Ding N, Meegdes M, Erdkamp F, Heijns J, et al.
Breast Cancer Res Treat
. 2024 Feb;
205(2):287-302.
PMID: 38381274
Purpose: The aim was to determine whether the real-world first-line progression-free survival (PFS) of patients diagnosed with de novo human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer...